Genomic classification and risk stratification of bladder cancer

Damiano Fantini, Joshua J. Meeks*

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Bladder cancer is the fourth most common cancer in men and fifth most common overall. The use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the molecular defects of tumors, and this information could be combined with other clinical data, such as tumor histology and TNM staging, with the goal of precise tumor classification. In many settings, targeted NGS is evaluated in patients with first- and second-line metastatic cancer. Yet, in the decade to come we anticipate increased application of precision oncology at all stages of bladder cancer with the aim of customizing cancer treatment. Here, we review the genomic and transcriptomic features associated with risk stratification in bladder cancer and summarize the current efforts for precision oncology in localized urothelial carcinomas.

Original languageEnglish (US)
Pages (from-to)1751-1757
Number of pages7
JournalWorld journal of urology
Volume37
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Urinary Bladder Neoplasms
Neoplasm Staging
Neoplasms
Histology
Carcinoma
Therapeutics

Keywords

  • Biomarker
  • Bladder cancer
  • Classifier
  • Genetic mutation
  • Risk-classification

ASJC Scopus subject areas

  • Urology

Cite this

@article{040b54a8b14d438b99dfb9d1fd1fc619,
title = "Genomic classification and risk stratification of bladder cancer",
abstract = "Bladder cancer is the fourth most common cancer in men and fifth most common overall. The use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the molecular defects of tumors, and this information could be combined with other clinical data, such as tumor histology and TNM staging, with the goal of precise tumor classification. In many settings, targeted NGS is evaluated in patients with first- and second-line metastatic cancer. Yet, in the decade to come we anticipate increased application of precision oncology at all stages of bladder cancer with the aim of customizing cancer treatment. Here, we review the genomic and transcriptomic features associated with risk stratification in bladder cancer and summarize the current efforts for precision oncology in localized urothelial carcinomas.",
keywords = "Biomarker, Bladder cancer, Classifier, Genetic mutation, Risk-classification",
author = "Damiano Fantini and Meeks, {Joshua J.}",
year = "2019",
month = "9",
day = "1",
doi = "10.1007/s00345-018-2558-2",
language = "English (US)",
volume = "37",
pages = "1751--1757",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "9",

}

Genomic classification and risk stratification of bladder cancer. / Fantini, Damiano; Meeks, Joshua J.

In: World journal of urology, Vol. 37, No. 9, 01.09.2019, p. 1751-1757.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Genomic classification and risk stratification of bladder cancer

AU - Fantini, Damiano

AU - Meeks, Joshua J.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Bladder cancer is the fourth most common cancer in men and fifth most common overall. The use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the molecular defects of tumors, and this information could be combined with other clinical data, such as tumor histology and TNM staging, with the goal of precise tumor classification. In many settings, targeted NGS is evaluated in patients with first- and second-line metastatic cancer. Yet, in the decade to come we anticipate increased application of precision oncology at all stages of bladder cancer with the aim of customizing cancer treatment. Here, we review the genomic and transcriptomic features associated with risk stratification in bladder cancer and summarize the current efforts for precision oncology in localized urothelial carcinomas.

AB - Bladder cancer is the fourth most common cancer in men and fifth most common overall. The use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the molecular defects of tumors, and this information could be combined with other clinical data, such as tumor histology and TNM staging, with the goal of precise tumor classification. In many settings, targeted NGS is evaluated in patients with first- and second-line metastatic cancer. Yet, in the decade to come we anticipate increased application of precision oncology at all stages of bladder cancer with the aim of customizing cancer treatment. Here, we review the genomic and transcriptomic features associated with risk stratification in bladder cancer and summarize the current efforts for precision oncology in localized urothelial carcinomas.

KW - Biomarker

KW - Bladder cancer

KW - Classifier

KW - Genetic mutation

KW - Risk-classification

UR - http://www.scopus.com/inward/record.url?scp=85056481018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056481018&partnerID=8YFLogxK

U2 - 10.1007/s00345-018-2558-2

DO - 10.1007/s00345-018-2558-2

M3 - Article

C2 - 30421072

AN - SCOPUS:85056481018

VL - 37

SP - 1751

EP - 1757

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 9

ER -